Nagi G. Ayad

3.2k total citations · 1 hit paper
59 papers, 2.2k citations indexed

About

Nagi G. Ayad is a scholar working on Molecular Biology, Cell Biology and Genetics. According to data from OpenAlex, Nagi G. Ayad has authored 59 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Biology, 14 papers in Cell Biology and 10 papers in Genetics. Recurrent topics in Nagi G. Ayad's work include Protein Degradation and Inhibitors (20 papers), Microtubule and mitosis dynamics (12 papers) and Histone Deacetylase Inhibitors Research (12 papers). Nagi G. Ayad is often cited by papers focused on Protein Degradation and Inhibitors (20 papers), Microtubule and mitosis dynamics (12 papers) and Histone Deacetylase Inhibitors Research (12 papers). Nagi G. Ayad collaborates with scholars based in United States, Spain and India. Nagi G. Ayad's co-authors include Marc W. Kirschner, Susannah Rankin, Wenyi Wei, Yong Wan, William G. Kaelin, Claes Wahlestedt, Claude‐Henry Volmar, Clara Penas, Ricardo J. Komotar and Stephan C. Schürer and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Nagi G. Ayad

55 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex

2004 400 citations Nagi G. Ayad, Marc W. Kirschner et al. profile →

Peers

Countries citing papers authored by Nagi G. Ayad

Since Specialization

Citations

This map shows the geographic impact of Nagi G. Ayad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nagi G. Ayad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nagi G. Ayad more than expected).

Fields of papers citing papers by Nagi G. Ayad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nagi G. Ayad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nagi G. Ayad. The network helps show where Nagi G. Ayad may publish in the future.

Co-authorship network of co-authors of Nagi G. Ayad

This figure shows the co-authorship network connecting the top 25 collaborators of Nagi G. Ayad. A scholar is included among the top collaborators of Nagi G. Ayad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nagi G. Ayad. Nagi G. Ayad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients 2025 ·Scientific Reports ·(unknown), (unknown), (unknown), (unknown), (unknown), Nina S. Kadan‐Lottick, Derek Hanson, Nagi G. Ayad	1
2	Kinome-Wide Virtual Screening by Multi-Task Deep Learning 2024 ·International Journal of Molecular Sciences ·(unknown), Bryce K. Allen, Vasileios Stathias, Nagi G. Ayad, Stephan C. Schürer	3
3	Glutaminase 2 as a therapeutic target in glioblastoma 2024 ·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·(unknown), (unknown), Emma Rowland, (unknown), Nagi G. Ayad	2
4	Loss of BRD4 induces cell senescence in HSC/HPCs by deregulating histone H3 clipping 2023 ·EMBO Reports ·(unknown), (unknown), Ying Guo, (unknown), (unknown), Guo Ge, (unknown), (unknown), Ganqian Zhu, Peng Zhang, Zhenqing Ye, Edward A. Medina, Nagi G. Ayad, Ruben A. Mesa, Stephen D. Nimer, Cheng‐Ming Chiang, Mingjiang Xu, Yidong Chen, Feng‐Chun Yang	14
5	A Druggable UHRF1/DNMT1/GLI Complex Regulates Sonic Hedgehog–Dependent Tumor Growth 2022 ·Molecular Cancer Research ·Fan Yang, Jezabel Rodríguez‐Blanco, Jun Long, Marzena Swiderska‐Syn, (unknown), (unknown), Chen Shen, Anmada Nayak, Yuguang Ban, (unknown), (unknown), Heather J. McCrea, Anthony J. Capobianco, Nagi G. Ayad, David J. Robbins	6
6	Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma 2022 ·World Neurosurgery ·Vaidya Govindarajan, Ashish H. Shah, (unknown), (unknown), (unknown), Daniel G. Eichberg, Evan Luther, Victor M. Lu, Alexis A. Morell, Michael E. Ivan, Ricardo J. Komotar, Nagi G. Ayad, Macarena de la Fuente	12
7	BET protein inhibition promotes non-myeloid cell mediated neuroprotection after rodent spinal cord contusion 2022 ·Experimental Neurology ·Susana R. Cerqueira, (unknown), Ha Eun Lee, Nagi G. Ayad, Jae K. Lee	3
8	A multiparametric pharmacogenomic strategy for drug repositioning predicts therapeutic efficacy for glioblastoma cell lines 2021 ·Neuro-Oncology Advances ·Ashish H. Shah, (unknown), (unknown), Tara T. Doucet-O’Hare, Vasileios Stathias, Iahn Cajigas, Macarena de la Fuente, Vaidya Govindarajan, Alexis A. Morell, Daniel G. Eichberg, Evan Luther, Victor M. Lu, John D. Heiss, Ricardo J. Komotar, Michael E. Ivan, Stephan C. Schürer, Mark R. Gilbert, Nagi G. Ayad	2
9	Organoid Models of Glioblastoma and Their Role in Drug Discovery 2021 ·Frontiers in Cellular Neuroscience ·(unknown), Michael E. Ivan, Nagi G. Ayad, Zane Zeier	57
10	Time series modeling of cell cycle exit identifies Brd4 dependent regulation of cerebellar neurogenesis 2019 ·Nature Communications ·Clara Penas, (unknown), Vasileios Stathias, Jun Long, Sze Kiat Tan, José M. Mier, Yin Fang, Camilo Valdes, Jezabel Rodríguez‐Blanco, Cheng-Ming Chiang, David J. Robbins, Daniel J. Liebl, Jae K. Lee, Mary E. Hatten, Jennifer Clarke, Nagi G. Ayad	22
11	Prenatal arsenic exposure alters the placental expression of multiple epigenetic regulators in a sex-dependent manner 2019 ·Environmental Health ·(unknown), (unknown), (unknown), David A. Armstrong, (unknown), (unknown), Anthony J. Capobianco, Nagi G. Ayad, Carmen J. Marsit, Zhigang Li, Margaret R. Karagas, David J. Robbins	29
12	Bromodomain and extraterminal domain-containing protein inhibition attenuates acute inflammation after spinal cord injury 2018 ·Experimental Neurology ·(unknown), James S. Choi, Ha Eun Lee, Sze Kiat Tan, Nagi G. Ayad, Jae K. Lee	39
13	Drug and disease signature integration identifies synergistic combinations in glioblastoma 2018 ·Nature Communications ·Vasileios Stathias, (unknown), (unknown), Michele Forlin, Winston Walters, (unknown), Michael Durante, Siôn L. Williams, J. William Harbour, Claude‐Henry Volmar, Nicholas Lyons, Claes Wahlestedt, Regina M. Graham, Michael E. Ivan, Ricardo J. Komotar, Jann N. Sarkaria, Aravind Subramanian, Todd R. Golub, Stephan C. Schürer, Nagi G. Ayad	67
14	Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme 2018 ·Frontiers in Oncology ·(unknown), (unknown), Macarena de la Fuente, Nagi G. Ayad	10
15	Identification of a Novel Class of BRD4 Inhibitors by Computational Screening and Binding Simulations 2017 ·ACS Omega ·Bryce K. Allen, Saurabh Mehta, S.W. Ember, Jin-Yi Zhu, E. Schönbrunn, Nagi G. Ayad, Stephan C. Schürer	28
16	Epigenetic Pathways and Glioblastoma Treatment: Insights From Signaling Cascades 2014 ·Journal of Cellular Biochemistry ·Bryce K. Allen, Vasileios Stathias, (unknown), D. Vidović, (unknown), Anthony J. Capobianco, Jennifer Clarke, Stephan C. Schürer, David J. Robbins, Nagi G. Ayad	25
17	BET bromodomain proteins are required for glioblastoma cell proliferation 2014 ·Epigenetics ·Chiara Pastori, (unknown), Clara Penas, Claude‐Henry Volmar, Andrea L. Johnstone, Shaun P. Brothers, Regina M. Graham, Bryce K. Allen, Jann N. Sarkaria, Ricardo J. Komotar, Claes Wahlestedt, Nagi G. Ayad	113
18	Sororin, a Substrate of the Anaphase- Promoting Complex, Is Required for Sister Chromatid Cohesion in Vertebrates 2005 ·Molecular Cell ·Susannah Rankin, Nagi G. Ayad, Marc W. Kirschner	7
19	Sororin, a Substrate of the Anaphase- Promoting Complex, Is Required for Sister Chromatid Cohesion in Vertebrates 2005 ·Molecular Cell ·Susannah Rankin, Nagi G. Ayad, Marc W. Kirschner	198
20	The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC–Cdc20 complex 2004 ·Nature Cell Biology ·Min Sup Song, Su Jeong Song, Nagi G. Ayad, (unknown), Joo‐Hyeon Lee, (unknown), Ho Lee, (unknown), Young Tae Kim, Hojoong Kim, Jin Woo Kim, Eui‐Ju Choi, Marc W. Kirschner, Dae‐Sik Lim	260

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact